Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1089-7623
    Source: AIP Digital Archive
    Topics: Physics , Electrical Engineering, Measurement and Control Technology
    Notes: Key objectives of the first ten years of ITER operation are the investigation of the physics of burning plasmas and the demonstration of long-pulse ignited plasma technologies. These include studies of plasma confinement and stability, divertor operation, disruption mitigation and control, noninductive current drive, and steady state operation under conditions when the plasma is heated predominantly by alpha particles. The ITER operational plan envisages two and a half years for commissioning and initial operation with hydrogen plasmas at up to 100 MW of auxiliary heating power when initial tests of divertor operation and evaluation of disruption effects will be made. In order to meet the operational and programmatic goals, it will be necessary to make a wide range of plasma measurements. In this article the preliminary operational plan and physics program are presented and the implications for plasma measurements are outlined. © 1997 American Institute of Physics.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1089-7623
    Source: AIP Digital Archive
    Topics: Physics , Electrical Engineering, Measurement and Control Technology
    Notes: Key objectives of the first ten years of ITER operation are the investigation of the physics of burning plasmas and the demonstration of long-pulse ignited plasma technologies. These include studies of plasma confinement and stability, divertor operation, disruption mitigation and control, noninductive current drive, and steady state operation under conditions when the plasma is heated predominantly by alpha particles. The ITER operational plan envisages two and a half years for commissioning and initial operation with hydrogen plasmas at up to 100 MW of auxiliary heating power when initial tests of divertor operation and evaluation of disruption effects will be made. In order to meet the operational and programmatic goals, it will be necessary to make a wide range of plasma measurements. In this article the preliminary operational plan and physics program are presented and the implications for plasma measurements are outlined. © 1997 American Institute of Physics.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    [S.l.] : American Institute of Physics (AIP)
    Physics of Fluids 30 (1987), S. 1489-1496 
    ISSN: 1089-7666
    Source: AIP Digital Archive
    Topics: Physics
    Notes: For sustained discharges at high values of the pinch parameter aitch-theta large disturbances appear on the plasma current, loop voltage, and toroidal magnetic field signals. An increase of both plasma resistance and magnetohydrodynamic (MHD) activity measured at the edge is observed. The onset of such phenomena is found at values of aitch-theta〉1.5 and the amplitude of the disturbances increases with aitch-theta. The oscillations are interpreted as the effect of major current redistributions occurring periodically in the central region of the plasma. Relating experimental field profiles and aitch-theta values, the effect of the current redistribution is the recovery of the on axis q value when a lower limit is exceeded. From the experimental measurements such a lower limit has been found to be approximately q(0)≥2a/(3R).
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Nuclear Instruments and Methods In Physics Research 207 (1983), S. 35-48 
    ISSN: 0167-5087
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Energy, Environment Protection, Nuclear Power Engineering , Physics
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    ISSN: 1432-0827
    Keywords: Goserelin ; Uterine leiomyomata ; Bone loss
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Medicine , Physics
    Notes: Abstract We evaluated the effects on bone mineral density (BMD) of a 12-month treatment with goserelin depot, a gonadotropin-releasing hormone agonist, in a group of women with symptomatic uterine myomas requiring hysterectomy. Sixteen women, mean age 45.6±5.0, reporting menorrhagia associated with uterine myomas, candidates for hysterectomy, were scheduled to be treated with goserelin depot for 12 months. BMD was measured at the vertebral (L2–L4) and proximal femur level (femoral neck and trochanter) at the start of therapy and 6, 12, and 18 months later using dual energy X-ray absorptiometry (Hologic QDR 1000/W). The patients were followed for a minimum of 6 months after the end of treatment. Thirteen of the 16 women enrolled completed the treatment and three suspended it after 5, 6, and 7 months, respectively, because of side effects (hot flashes, insomnia, depression). Of the 13 women who completed the treatment, three underwent hysterectomy because of myoma regrowth and the recurrence of symptoms 3–18 months later; four reached the menopause 5–16 months later, and six were all menstruating normally with a follow-up varying from 6 to 18 months. After 12 months of therapy we observed a bone loss at vertebral, femoral neck, and trochanter of 4.4% (P〈0.05 versus baseline; P = not significant versus 6 months), 7.5% (P〈0.01 versus baseline, P〈0.01 versus 6 months), and 7.6% (P〈0.001 versus baseline, P〈0.05 versus 6 months), respectively. Six months later, BMD increased slightly and not significantly at different sites (0.9% at the spine, and 0.3% at femoral neck, and 1.1% at trochanter). A 12-month treatment with goserelin may avoid the need for hysterectomy in women over 40 with symptomatic myomas. However, this therapy is associated with a marked bone loss which is not significantly reversed at its suspension.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    ISSN: 1432-0827
    Keywords: Key words: Bone loss — Bone turnover — Ipriflavone — Vertebral bone mass.
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Medicine , Physics
    Notes: Abstract. One hundred ninety-eight postmenopausal women (aged 50–65 years) with vertebral bone density (VBD) 1 SD below the mean value for normal, age-matched, postmenopausal subjects were enrolled in six Italian centers and 134 completed 2 years of treatment. All subjects were randomly allocated to a 2-year treatment with oral ipriflavone (200 mg t.i.d.) or a matching placebo, according to a double-blind, parallel group design. All patients also received an oral daily calcium supplement of 1 g as calcium carbonate. VBD and markers of bone turnover were measured at baseline, and every 6 months. A complete routine analysis of liver and kidney functions along with hematological parameters were measured before and at the end of treatment period. The valid completers analysis showed a significant increase of VBD in ipriflavone-treated women with average percent changes of +1.4 after 1 year, and +1% at the end of treatment period (P 〈 0.05). The placebo group presented a significant decrease of VBD after 2 years of treatment (P 〈 0.05). The difference between treatments was significant (P 〈 0.01). The intention to treat analysis confirmed the significant decrease of VBD in the placebo group, with no changes in ipriflavone-treated women. Skeletal ALP significantly decreased in ipriflavone-treated women (P 〈 0.05). Serum BGP and urine HOP/Cr showed a significant decrease only in ipriflavone-treated women, suggesting an inhibitory effect on bone turnover rate. Adverse reactions, mainly gastrointestinal, occurred to a similar extent in the two treatment groups. The evaluation of patients' compliance, assessed by residual tablets count, revealed a drug intake of more than 80% after 2 years in 92.5% and 92.8% of patients treated with ipriflavone or placebo, respectively. This study demonstrates that ipriflavone can prevent bone loss in postmenopausal women with low bone mass.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    ISSN: 1432-0827
    Keywords: Key words: Ipriflavone — Bone mass — Postmenopausal osteopenia.
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Medicine , Physics
    Notes: Abstract. We present the results of two multicenter, double-blind, placebo-controlled, 2-year studies to evaluate the efficacy and tolerability of ipriflavone in postmenopausal women (PMW) with low bone mass. 453 PMW (aged 50–65 years) with a vertebral (VMD) or radial (RMD) mineral density value 1 SD lower compared with age-matched controls, were randomly selected to receive oral ipriflavone (200 mg T.I.D. at meals) or matching placebo, plus 1 g oral calcium daily. Vertebral (study A, by dual X-ray absorptiometry-DXA) and radial (study B, by dual photon absorptiometry-DPA) bone density, serum bone Gla-protein (BGP), and urinary hydroxyproline/creatinine (HOP/Cr) were measured every 6 months. In both studies, the Valid Completers (VC) analysis showed a maintenance of bone mass in ipriflavone-treated women, whereas in the placebo group, bone mineral density (BMD) was significantly decreased. The final outcome was a bone-sparing effect of 1.6% in study A, and of 3.5% in study B after 2 years. The Intention to Treat (ITT) analysis confirmed the decrease in the placebo group, with no changes in ipriflavone-treated women. A significant (P 〈 0.05) between-treatment difference was found in both studies. Biochemical markers of bone turnover decreased in patients treated with ipriflavone, thus suggesting a reduction of bone turnover rate. Twenty-six women treated with ipriflavone and 28 receiving the placebo dropped out because of side effects, mainly gastrointestinal. The compliance to the oral long-term treatment was good. The results of these studies show that ipriflavone is able to prevent both axial and peripheral bone loss in PMW with low bone mass, and is well tolerated.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    ISSN: 1432-0827
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Medicine , Physics
    Notes: Abstract. Bone quality is important for the success of joint prostheses implantation, and the assessment of bone density after total knee arthroplasty by means of dual-energy X-ray absorptiometry may be useful for monitoring implant stability. The aim of this study is to suggest a validated analysis protocol for the assessment of bone status after total knee arthroplasty. A dedicated densitometric analysis protocol of five regions of interest was designed, and 10 subjects who had received an uncemented knee prosthesis (8 females and 2 males, aged 55–74 years) underwent three consecutive scans in posteroanterior and lateral projections, with repositioning after each scan to test the suitability and reproducibility of the protocol. The reproducibility of the measurement of bone mineral content and density in the femoral and tibial regions ranged, respectively, from 2.1% to 4.1%, from 0.9% to 2.6% for the posteroanterior scans, and from 2.7% to 5.6% and from 2.3% to 4.7% for the lateral scans, depending on the considered region. Our results confirm that the suggested protocol allows precise assessment of bone mineral content and density, and that dual-energy X-ray absorptiometry is reliable for the evaluation of bone mass around prosthetic implants.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    ISSN: 1432-1041
    Keywords: menopause — oestradiol ; conjugated oestrogens ; transdermal delivery ; postmenopausal women ; medroxyprogesterone ; acetate ; plasma lipids ; adverse effects
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary In an open, randomized, comparative, between-patient trial, 45 postmenopausal women were treated for 4 months with cyclical transdermal oestradiol 0.05 mg per day or oral conjugated equine oestrogens 0.625 mg per day, in both cases, plus, medroxyprogesterone acetate 10 mg per day on the last 8 days of each cycle. Similar relief from postmenopausal symptoms was obtained with both treatments. Post-treatment histological evaluation of the endometrium did not reveal neoplastic or hyperplastic change in any patient. Early follicular-phase plasma oestradiol levels were observed only after transdermal oestradiol. There was a significant reduction in serum total cholesterol and LDL cholesterol in both treatment groups, with no difference between treatments, whereas serum triglyceride levels were decreased only by transdermal oestradiol. Plasma calcium and phosphorus fell significantly and serum intact parathyroid hormone rose significantly, with no difference between the therapies. No significant changes were observed in clotting factors. Transdermal oestradiol appears to be an effective and safe hormonal replacement therapy, and this route of administration may be responsible for the more useful action of the drug on serum lipids and plasma oestradiol levels.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Electronic Resource
    Electronic Resource
    Springer
    Astrophysics and space science 265 (1999), S. 355-359 
    ISSN: 1572-946X
    Source: Springer Online Journal Archives 1860-2000
    Topics: Physics
    Notes: Abstract In this paper we discuss the characteristics of the stellar content of the galactic bulge excluding the stars within a few parsec from the galactic center. The bulge clusters and the field stars are comparedto the disk population. A scenario with a flattened bulge extending toabout 3–4 Kpc from the galactic center is presented. There is evidencefor an old bulge stellar population, decoupled from the disk.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...